SEC Comment Letter for SOLIGENIX, INC. (SNGX) (CIK 0000812796) (SNGX) — Feb 5, 2007

SOLIGENIX, INC. (SNGX) (CIK 0000812796)
Date: Feb. 5, 2007 · CIK: 0000812796 · Accession: 0000000000-07-006154

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 000-16929

Date

January 30, 2007

Author

Jim B. Rosenberg

Form

UPLOAD

Company

SOLIGENIX, INC. (SNGX) (CIK 0000812796)

Letter

Via Facsimile and U.S. Mail Mail Stop 6010 January 30, 2007 Mr. Evan Myrianthopoulos Chief Financial Officer DOR Biopharma, Inc. 1101 Brickell Avenue, 701-S Miami, FL 33131 Re: DOR Biopharma, Inc. Form 10-KSB for the Fiscal Year Ended December 31, 2005 Filed March 31, 2006 File No. 000-16929

Dear Mr. Myrianthopoulos:

We have completed our review of your Form 10-KSB and have no further comments at this time. S i n c e r e l y , J i m B . R o s e n b e r g Senior Assistant Chief Accountant

Show Raw Text

Via Facsimile and U.S. Mail Mail Stop 6010          January 30, 2007   Mr. Evan Myrianthopoulos Chief Financial Officer  DOR Biopharma, Inc. 1101 Brickell Avenue, 701-S Miami, FL 33131
Re: DOR Biopharma, Inc.
 Form 10-KSB for the Fiscal Year Ended December 31, 2005
  Filed March 31, 2006
  File No. 000-16929

Dear Mr. Myrianthopoulos:

 We have completed our review of your Form 10-KSB and have no further
comments at this time.           S i n c e r e l y ,            J i m  B .  R o s e n b e r g         Senior Assistant Chief Accountant

SecProbe.io